Global Dilated Cardiomyopathy Therapeutics Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Secondary Research
1.3.2 Primary Research
1.4 List of Abbreviations
1.5 Assumptions and Stipulations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Dilated Cardiomyopathy Therapeutics Market (2018 & 2026)
2.2 Comparative Analysis: Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2018 & 2026 (Value %)

Chapter 3 Global Dilated Cardiomyopathy Therapeutics Market Overview
3.1 Market Definition and Overview
3.1.1 Classification of Cardiomyopathies
3.1.2 Market Drivers
3.1.2.1 Increasing number of heart failure cases worldwide will lead to rise in demand for effective medications, thereby driving market growth
3.1.3 Market Restraints
3.1.3.1 Side effects associated with DCM drugs could restrain market growth
3.1.3.2 Enhanced relief from use of devices without any side effects will restrain the dilated cardiomyopathy drugs market
3.1.4 Promising gene and stem cell therapies for DCM treatment may hamper the DCM drugs market growth
3.1.5 Market Opportunities
3.1.7 Increasing genericization of DCM drugs
3.2 Market Attractiveness Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2018
3.3 Epidemiology (Prevalence, Cause, Mortality Rate)
3.4 Epidemiology Studies on Dilated Cardiomyopathy
3.5 Causes and Mortality
3.6 Event Impact Analysis
3.7 Competitive Landscape, by Key Players, 2018 (Value %)
3.7.1 Market share by key players, 2018 (Value %)

Chapter 4 Global Dilated Cardiomyopathy Therapeutics Market, by Drug Class
4.1 Introduction
4.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Drug Class 2016 – 2026 (USD Million)
4.2 Aldosterone Antagonists
4.2.1 Global Aldosterone Antagonists Market Revenue, 2016 - 2026 (USD Million)
4.3 Angiotensin-Converting Enzymes (ACE) Inhibitors
4.3.1 Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market Revenue, 2016 - 2026 (USD Million)
4.4 Angiotensin II Receptor Blocker (ARBs)
4.4.1 Global Angiotensin II Receptor Blockers (ARBs) Market Revenue, 2016 - 2026 (USD Million)
4.5 Beta-Blockers
4.5.1 Global Beta-Blockers Market Revenue, 2016 - 2026 (USD Million)

Chapter 5 Pipeline Analysis of Global Dilated Cardiomyopathy Therapeutics Market
5.1 Pipeline Analysis
5.1.1 Pipeline Analysis : Dilated Cardiomyopathy Therapeutics Market

Chapter 6 Global Dilated Cardiomyopathy Therapeutics Market, by Geography
6.1 Introduction
6.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2016 - 2026 (USD Million)
6.2 North America
6.2.1 North America Dilated Cardiomyopathy Therapeutics Market Revenue, 2016 - 2026 (USD Million)
6.3 Europe
6.3.1 Europe Dilated Cardiomyopathy Therapeutics Market Revenue, 2016 - 2026 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Dilated Cardiomyopathy Therapeutics market Revenue, 2016 - 2026 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 Rest of the World Dilated Cardiomyopathy Therapeutics Market Revenue, 2016 - 2026 (USD Million)

Chapter 7 Recommendations
7.1 Dilated phase of hypertrophic cardiomyopathy
7.2 Genetic Intervention

Chapter 8 Company Profiles
8.1 Array BioPharma, Inc.
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategies
8.1.5 Recent Developments
8.2 AstraZeneca plc
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Product Portfolio
8.2.4 Business Strategies
8.2.5 Recent Developments
8.3 Celladon Corporation
8.3.1 Company Overview
8.3.2 Financial Overview
8.3.3 Product Portfolio
8.3.4 Business Strategies
8.3.5 Recent Developments
8.4 GlaxoSmithKline plc
8.4.1 Company Overview
8.4.2 Financial Overview
8.4.3 Product Portfolio
8.4.4 Business Strategies
8.4.5 Recent Developments
8.5 Janssen Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Overview
8.5.3 Product Portfolio
8.5.4 Business Strategies
8.5.5 Recent Developments
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Overview
8.6.3 Product Portfolio
8.6.4 Business Strategies
8.6.5 Recent Developments
8.7 Novartis International AG
8.7.1 Company Overview
8.7.2 Financial Overview
8.7.3 Product Portfolio
8.7.4 Business Strategies
8.7.5 Recent Developments
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Overview
8.8.3 Product Portfolio
8.8.4 Business Strategies
8.8.5 Recent Developments
8.9 Sanofi S.A.
8.9.1 Company Overview
8.9.2 Financial Overview
8.9.3 Product Portfolio
8.9.4 Business Strategies
8.9.5 Recent Developments
8.10 Teva Pharmaceutical Industries Ltd.
8.10.1 Company Overview
8.10.2 Financial Overview
8.10.3 Product Portfolio
8.10.4 Business Strategies
8.10.5 Recent Developments
8.11 Vericel Corporation
8.11.1 Company Overview
8.11.2 Financial Overview
8.11.3 Product Portfolio
8.11.4 Business Strategies
8.11.5 Recent Developments